PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65:87-108; PMID:25651787; http://dx.doi.org/10.3322/caac.21262
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90; PMID:21296855; http://dx.doi.org/10.3322/caac.20107
   PubMed Web of Science ®Google Scholar
• Qin A, Coffey DG, Warren EH, Ramnath N. Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer. Cancer Med 2016; 5:2567-78; PMID:27416962; http://dx.doi.org/10.1002/cam4.819
   PubMed Web of Science ®Google Scholar
• Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res 2016; 5:288-300; PMID:27413711; http://dx.doi.org/10.21037/tlcr.2016.06.07
   PubMed Web of Science ®Google Scholar
• Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, Lai Z, Markovets A, Vivancos A, Kuang Y et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med 2015; 21:560-2; PMID:25939061; http://dx.doi.org/10.1038/nm.3854
   PubMed Web of Science ®Google Scholar
• Wang S, Tsui ST, Liu C, Song Y, Liu D. EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer. J Hematol Oncol 2016; 9:59; http://dx.doi.org/10.1186/s13045-016-0290-1
   PubMed Web of Science ®Google Scholar
• Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol 2016; 9:34; PMID:27071706; http://dx.doi.org/10.1186/s13045-016-0268-z
   PubMed Web of Science ®Google Scholar
• Wu J, Savooji J, Liu D. Second- and third-generation ALK inhibitors for non-small cell lung cancer. J Hematol Oncol 2016; 9:19; PMID:26951079; http://dx.doi.org/10.1186/s13045-016-0251-8
   PubMed Web of Science ®Google Scholar
• Alexander GS, Palmer JD, Tuluc M, Lin J, Dicker AP, Bar-Ad V, Harshyne LA, Louie J, Shaw CM, Hooper DC et al. Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy. J Hematol Oncol 2016; 9:96; PMID:27663515; http://dx.doi.org/10.1186/s13045-016-0328-4
   PubMed Web of Science ®Google Scholar
• Dang TO, Ogunniyi A, Barbee MS, Drilon A. Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer. Expert Rev Anticancer Ther 2016; 16:13-20; PMID:26588948; http://dx.doi.org/10.1586/14737140.2016.1123626
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Eng J Med 2015; 373:123-35; PMID:26028407; http://dx.doi.org/10.1056/NEJMoa1504627
   PubMed Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Eng J Med 2015; 372:2018-28; PMID:25891174; http://dx.doi.org/10.1056/NEJMoa1501824
   PubMed Web of Science ®Google Scholar
• Ma W, Gilligan BM, Yuan J, Li T. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol 2016; 9:47; PMID:27234522; http://dx.doi.org/10.1186/s13045-016-0277-y
   PubMed Web of Science ®Google Scholar
• Geyer MB, Brentjens RJ. Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells. Cytotherapy 2016; 18:1393-409; PMID:27592405; http://dx.doi.org/10.1016/j.jcyt.2016.07.003
   PubMed Web of Science ®Google Scholar
• Park JH, Geyer MB, Brentjens RJ. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood 2016; 127:3312-20; PMID:27207800; http://dx.doi.org/10.1182/blood-2016-02-629063
   PubMed Web of Science ®Google Scholar
• Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. Nat Rev Clin Oncol 2016; 13:370-83; PMID:27000958
   PubMed Web of Science ®Google Scholar
• Li K, Pan X, Bi Y, Xu W, Chen C, Gao H, Shi B, Jiang H, Yang S, Jiang L et al. Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinoma. Oncotarget 2016; 7:2496-507; PMID:26684028; http://dx.doi.org/10.18632/oncotarget.6595
   PubMed Web of Science ®Google Scholar
• Feng K, Guo Y, Dai H, Wang Y, Li X, Jia H, Han W. Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer. Sci China Life Sci 2016; 59:468-79; PMID:26968708; http://dx.doi.org/10.1007/s11427-016-5023-8
   PubMed Web of Science ®Google Scholar
• Situ D, Wang J, Ma Y, Zhu Z, Hu Y, Long H, Rong T. Expression and prognostic relevance of MUC1 in stage IB non-small cell lung cancer. Med Oncol 2011; 28 Suppl 1:S596-604; PMID:21116877; http://dx.doi.org/10.1007/s12032-010-9752-4
   PubMed Web of Science ®Google Scholar
• Kawaguchi T, Sho M, Tojo T, Yamato I, Nomi T, Hotta K, Hamada K, Suzaki Y, Sugiura S, Kushibe K et al. Clinical significance of prostate stem cell antigen expression in non-small cell lung cancer. Jpn J Clin Oncol 2010; 40:319-26; PMID:20085909; http://dx.doi.org/10.1093/jjco/hyp181
   PubMed Web of Science ®Google Scholar
• Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 1998; 95:1735-40; PMID:9465086; http://dx.doi.org/10.1073/pnas.95.4.1735
   PubMed Web of Science ®Google Scholar
• Zou Q, Yang L, Yang Z, Huang J, Fu X. PSCA and Oct-4 expression in the benign and malignant lesions of gallbladder: implication for carcinogenesis, progression, and prognosis of gallbladder adenocarcinoma. BioMed Res Int 2013; 2013:648420
   PubMed Web of Science ®Google Scholar
• Zhao X, Wang F, Hou M. Expression of stem cell markers nanog and PSCA in gastric cancer and its significance. Oncol Lett 2016; 11:442-8; PMID:26870231; http://dx.doi.org/10.3892/ol.2015.3884
   PubMed Web of Science ®Google Scholar
• The MICAD Research Team. [125I]Anti-prostate stem cell antigen antibody. Molecular Imaging and Contrast Agent Database (MICAD) 2004; PMID:20641839
   PubMedGoogle Scholar
• Ross S, Spencer SD, Holcomb I, Tan C, Hongo J, Devaux B, Rangell L, Keller GA, Schow P, Steeves RM et al. Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res 2002; 62:2546-53; PMID:11980648
   PubMed Web of Science ®Google Scholar
• Matsueda S, Kobayashi K, Nonaka Y, Noguchi M, Itoh K, Harada M. Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2(+) patients with hormone-refractory prostate cancer. Cancer Immunol Immun 2004; 53:479-89; PMID:14634796; http://dx.doi.org/10.1007/s00262-003-0464-x
   PubMed Web of Science ®Google Scholar
• Matsueda S, Yao A, Ishihara Y, Ogata R, Noguchi M, Itoh K, Harada M. A prostate stem cell antigen-derived peptide immunogenic in HLA-A24- prostate cancer patients. Prostate 2004; 60:205-13; PMID:15176050; http://dx.doi.org/10.1002/pros.20038
   PubMed Web of Science ®Google Scholar
• Gu Z, Yamashiro J, Kono E, Reiter RE. Anti-prostate stem cell antigen monoclonal antibody 1G8 induces cell death in vitro and inhibits tumor growth in vivo via a Fc-independent mechanism. Cancer Res 2005; 65:9495-500; PMID:16230414; http://dx.doi.org/10.1158/0008-5472.CAN-05-2086
   PubMed Web of Science ®Google Scholar
• Abate-Daga D, Lagisetty KH, Tran E, Zheng Z, Gattinoni L, Yu Z, Burns WR, Miermont AM, Teper Y, Rudloff U et al. A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. Hum Gene Ther 2014; 25:1003-12; PMID:24694017; http://dx.doi.org/10.1089/hum.2013.209
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Amant F, Biankin AV, Budinská E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, Mælandsmo GM et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov 2014; 4:998-1013; PMID:25185190; http://dx.doi.org/10.1158/2159-8290.CD-14-0001
   PubMed Web of Science ®Google Scholar
• Dong R, Qiang W, Guo H, Xu X, Kim JJ, Mazar A, Kong B, Wei JJ. Histologic and molecular analysis of patient derived xenografts of high-grade serous ovarian carcinoma. J Hematol Oncol 2016; 9:92; PMID:27655386; http://dx.doi.org/10.1186/s13045-016-0318-6
   PubMed Web of Science ®Google Scholar
• Ye W, Jiang Z, Li GX, Xiao Y, Lin S, Lai Y, Wang S, Li B, Jia B, Li Y et al. Quantitative evaluation of the immunodeficiency of a mouse strain by tumor engraftments. J Hematol Oncol 2015; 8:59; PMID:26022250; http://dx.doi.org/10.1186/s13045-015-0156-y
   PubMed Web of Science ®Google Scholar
• Olafsen T, Gu Z, Sherman MA, Leyton JV, Witkosky ME, Shively JE, Raubitschek AA, Morrison SL, Wu AM, Reiter RE. Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. J Immunother 2007; 30:396-405; PMID:17457214; http://dx.doi.org/10.1097/CJI.0b013e318031b53b
   PubMed Web of Science ®Google Scholar
• Wilkie S, Picco G, Foster J, Davies DM, Julien S, Cooper L, Arif S, Mather SJ, Taylor-Papadimitriou J, Burchell JM et al. Retargeting of human t cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J Immunol 2008; 180:4901-9; PMID:18354214; http://dx.doi.org/10.4049/jimmunol.180.7.4901
   PubMed Web of Science ®Google Scholar
• Klebanoff CA, Rosenberg SA, Restifo NP. Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat Med 2016; 22:26-36; PMID:26735408; http://dx.doi.org/10.1038/nm.4015
   PubMed Web of Science ®Google Scholar
• Djureinovic D, Hallström BM, Horie M, Mattsson JS, La Fleur L, Fagerberg L, Brunnström H, Lindskog C, Madjar K, Rahnenführer J et al. Profiling cancer testis antigens in non-small-cell lung cancer. JCI Insight 2016; 1:e86837; PMID:27699219; http://dx.doi.org/10.1172/jci.insight.86837
   PubMed Web of Science ®Google Scholar
• Beatty GL, O'Hara M. Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps. Pharmacol Ther 2016; 166:30-9; PMID:27373504; http://dx.doi.org/10.1016/j.pharmthera.2016.06.010
   PubMed Web of Science ®Google Scholar
• Di S, Li Z. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects. Sci China Life Sci 2016; 59:360-9; PMID:26968709; http://dx.doi.org/10.1007/s11427-016-5025-6
   PubMed Web of Science ®Google Scholar
• Kakarla S, Chow KK, Mata M, Shaffer DR, Song XT, Wu MF, Liu H, Wang LL, Rowley DR, Pfizenmaier K et al. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol Ther 2013; 21:1611-20; PMID:23732988; http://dx.doi.org/10.1038/mt.2013.110
   PubMed Web of Science ®Google Scholar
• Zhou X, Li J, Wang Z, Chen Z, Qiu J, Zhang Y, Wang W, Ma Y, Huang N, Cui K et al. Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes. Neoplasia 2013; 15:544-53; PMID:23633926; http://dx.doi.org/10.1593/neo.13168
   PubMed Web of Science ®Google Scholar
• Morello A, Sadelain M, Adusumilli PS. Mesothelin-targeted CARs: driving T cells to solid tumors. Cancer Discov 2016; 6:133-46; PMID:26503962; http://dx.doi.org/10.1158/2159-8290.CD-15-0583
   PubMed Web of Science ®Google Scholar
• Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 2013; 31:71-5; PMID:23242161; http://dx.doi.org/10.1038/nbt.2459
   PubMed Web of Science ®Google Scholar
• Hillerdal V, Ramachandran M, Leja J, Essand M. Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice. BMC Cancer 2014; 14:30; PMID:24438073; http://dx.doi.org/10.1186/1471-2407-14-30
   PubMed Web of Science ®Google Scholar
• Wilkie S, van Schalkwyk MC, Hobbs S, Davies DM, van der Stegen SJ, Pereira AC, Burbridge SE, Box C, Eccles SA, Maher J. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol 2012; 32:1059-70; PMID:22526592; http://dx.doi.org/10.1007/s10875-012-9689-9
   PubMed Web of Science ®Google Scholar
• Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara VR et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 2015; 21:581-90; PMID:25939063; http://dx.doi.org/10.1038/nm.3838
   PubMed Web of Science ®Google Scholar
• Song DG, Ye Q, Poussin M, Harms GM, Figini M, Powell DJ Jr. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood 2012; 119:696-706; PMID:22117050; http://dx.doi.org/10.1182/blood-2011-03-344275
   PubMed Web of Science ®Google Scholar
• Hombach AA, Heiders J, Foppe M, Chmielewski M, Abken H. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells. Oncoimmunology 2012; 1:458-66; PMID:22754764; http://dx.doi.org/10.4161/onci.19855
   PubMed Web of Science ®Google Scholar
• Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, Zhang M, Vera J, Heslop HE, Rooney CM, Brenner MK, Dotti G. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 2010; 24:1160-70; PMID:20428207; http://dx.doi.org/10.1038/leu.2010.75
   PubMed Web of Science ®Google Scholar
• Perna SK, De Angelis B, Pagliara D, Hasan ST, Zhang L, Mahendravada A, Heslop HE, Brenner MK, Rooney CM, Dotti G et al. Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma. Clin Cancer Res 2013; 19:106-17; PMID:23149818; http://dx.doi.org/10.1158/1078-0432.CCR-12-2143
   PubMed Web of Science ®Google Scholar
• Perna SK, Pagliara D, Mahendravada A, Liu H, Brenner MK, Savoldo B, Dotti G. Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition. Clin Cancer Res 2014; 20:131-9; PMID:24097874; http://dx.doi.org/10.1158/1078-0432.CCR-13-1016
   PubMed Web of Science ®Google Scholar
• Markley JC, Sadelain M. IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. Blood 2010; 115:3508-19; PMID:20190192; http://dx.doi.org/10.1182/blood-2009-09-241398
   PubMed Web of Science ®Google Scholar
• Song W, Delyria ES, Chen J, Huang W, Lee JS, Mittendorf EA, Ibrahim N, Radvanyi LG, Li Y, Lu H et al. MUC1 glycopeptide epitopes predicted by computational glycomics. Int J Oncol 2012; 41:1977-84; PMID:23023583; http://dx.doi.org/10.3892/ijo.2012.1645
   PubMed Web of Science ®Google Scholar
• O'Hear C, Heiber JF, Schubert I, Fey G, Geiger TL. Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia. Haematologica 2015; 100:336-44; PMID:25480499; http://dx.doi.org/10.3324/haematol.2014.112748
   PubMed Web of Science ®Google Scholar
• Qin H, Cho M, Haso W, Zhang L, Tasian SK, Oo HZ, Negri GL, Lin Y, Zou J, Mallon BS et al. Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein. Blood 2015; 126:629-39; PMID:26041741; http://dx.doi.org/10.1182/blood-2014-11-612903
   PubMed Web of Science ®Google Scholar